US Biosecure Act: Impact on Indian pharma companies
Evolving trends for Big Pharma to benefit Syngene, says CFO Sibaji Biswas
Pharma & biotech industry propels ESG implementation with concerns over climate change & global supply disruptions
India seeks a seat at the drug services table
Integrating Strategies for Formulation Success
Syngene: Strong play on ‘China Switches’ in the CRAMS space
Syngene International Q1 earnings update
Navigating the Shift from China: The Future of Global Pharma Supply Chains
The Importance of Strategic Investments and Technological Advancements
The Blockbuster Biosimilar Drugs
